Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Menley & James urges FDA to withdraw reg requiring NDAs for epinephrine MDIs.

This article was originally published in The Tan Sheet

Executive Summary

FDA URGED TO WITHDRAW REG REQUIRING NDAs FOR EPINEPHRINE MDIs by Menley & James Laboratories in May 23 comments to the agency. Menley & James maintained that FDA has not provided "a reasonable basis to support the revocation of the generally recognized as safe and effective (GRAS/E) status of pressurized metered dose inhaler aerosol container dosage forms" for epinephrine, epinephrine bitartrate, and racephedrine hydrochloride.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel